Supernus Pharmaceuticals (SUPN) Accumulated Expenses (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Accumulated Expenses data on file, last reported at $101.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 40.49% year-over-year to $101.2 million in Q1 2026; TTM through Mar 2026 was $101.2 million, a 40.49% decrease from a year earlier, with the FY2025 full-year figure at $107.8 million, up 41.19% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $101.2 million, down from $107.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for SUPN reached as high as $184.5 million in Q3 2025 and fell as low as $76.4 million in Q4 2024.
• Historically, Accumulated Expenses has averaged $123.7 million across 5 years, with a median of $110.3 million in 2022.
• On a YoY basis, Accumulated Expenses climbed as much as 47.3% in 2023 and fell as far as 43.03% in 2023.
• Year by year, Accumulated Expenses stood at $96.3 million in 2022, then slipped by 17.41% to $79.6 million in 2023, then slipped by 4.04% to $76.4 million in 2024, then soared by 41.19% to $107.8 million in 2025, then decreased by 6.08% to $101.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $101.2 million in Q1 2026, $107.8 million in Q4 2025, and $184.5 million in Q3 2025.